NLRP3 and atherosclerosis: The reason is that as a human monoclonal antibody targeting IL-1β, canakinumab might exert cardiovascular benefits by mediating the activation of IL-1β and the NLRP3 inflammasome within the kidney, thus contributing to cardioprotection during atherosclerosis (56).